Rein Therapeutics (NASDAQ:RNTX) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Rein Therapeutics (NASDAQ:RNTX) posted its earnings results on Thursday. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.12), Zacks reports.

Rein Therapeutics Stock Performance

NASDAQ RNTX traded down $0.04 during trading on Friday, hitting $1.24. The stock had a trading volume of 2,025 shares, compared to its average volume of 107,064. The company has a market capitalization of $32.46 million, a PE ratio of -0.47 and a beta of 1.51. The company’s 50-day moving average price is $1.25 and its two-hundred day moving average price is $1.29. Rein Therapeutics has a 12 month low of $1.02 and a 12 month high of $2.40.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on RNTX shares. Citigroup lowered shares of Rein Therapeutics to a “hold” rating in a research note on Wednesday, January 21st. downgraded shares of Rein Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 21st. Wall Street Zen lowered shares of Rein Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 14th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $8.00.

Institutional Trading of Rein Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of Rein Therapeutics by 32.2% in the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Cable Car Capital LP bought a new position in Rein Therapeutics in the second quarter valued at $588,000. Geode Capital Management LLC grew its position in Rein Therapeutics by 15.1% in the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock valued at $330,000 after purchasing an additional 37,244 shares in the last quarter. State Street Corp increased its stake in Rein Therapeutics by 374.3% in the 4th quarter. State Street Corp now owns 75,904 shares of the company’s stock valued at $88,000 after buying an additional 59,900 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Rein Therapeutics in the 4th quarter valued at $72,000. 90.89% of the stock is currently owned by institutional investors and hedge funds.

About Rein Therapeutics

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.